The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply.
Publication
, Journal Article
Ravandi, F; Zhou, S; Short, N
Published in: JAMA Oncol
May 1, 2021
Duke Scholars
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
May 1, 2021
Volume
7
Issue
5
Start / End Page
784 / 785
Location
United States
Related Subject Headings
- Neoplasm, Residual
- Leukemia, Myeloid, Acute
- Humans
- High-Throughput Nucleotide Sequencing
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Ravandi, F., Zhou, S., & Short, N. (2021). The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply. JAMA Oncol, 7(5), 784–785. https://doi.org/10.1001/jamaoncol.2021.0128
Ravandi, Farhad, Shouhao Zhou, and Nicholas Short. “The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply.” JAMA Oncol 7, no. 5 (May 1, 2021): 784–85. https://doi.org/10.1001/jamaoncol.2021.0128.
Ravandi F, Zhou S, Short N. The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply. JAMA Oncol. 2021 May 1;7(5):784–5.
Ravandi, Farhad, et al. “The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply.” JAMA Oncol, vol. 7, no. 5, May 2021, pp. 784–85. Pubmed, doi:10.1001/jamaoncol.2021.0128.
Ravandi F, Zhou S, Short N. The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply. JAMA Oncol. 2021 May 1;7(5):784–785.
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
May 1, 2021
Volume
7
Issue
5
Start / End Page
784 / 785
Location
United States
Related Subject Headings
- Neoplasm, Residual
- Leukemia, Myeloid, Acute
- Humans
- High-Throughput Nucleotide Sequencing
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis